Company intelligence
Aldevron
A world where every cure is possible.
About Aldevron
Aldevron is proud to be part of Danaher. Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
Verified activity
Signals from Aldevron
8 published signals
Presence & Recognition
Aldevron is attending the CAR-TCR Summit in Boston from September 15-17 to discuss advancements in scalable CAR-T and TCR therapies.
Reported by Aldevron
Operations & Supply
Aldevron will close its U.S. offices on Labor Day, September 7th, and return to the office on Tuesday, September 8th.
Reported by Aldevron
Presence & Recognition
Aldevron is attending the RNA Vaccines & Therapeutics Conference in London to discuss innovations shaping the future of RNA medicines.
Reported by Aldevron
Presence & Recognition
Aldevron is hosting a webinar on September 8, 2026, titled How Early is Too Early to Start Thinking About Manufacturing? For gene-modified cell therapies, choices made during plasmid design can create advantages or challenges that persist all the way through commercialization.
Reported by Kimesha Hammett
Presence & Recognition
Aldevron welcomed Victoria Gray as part of the Advance Beyond symposium last year to recognize the first person to have their cells edited using CRISPR for sickle cell disease.
Reported by Kimesha Hammett
Presence & Recognition
Aldevron welcomed Victoria Gray as part of the Advance Beyond symposium last year to recognize the first person to have their cells edited using CRISPR for sickle cell disease.
Reported by Aldevron
Presence & Recognition
Aldevron is attending Advanced Therapies Europe in Barcelona next week to connect with the cell and gene therapy community.
Reported by Nicolò Sacchetti, PhD
Research & Knowledge
Aldevron published a blog exploring how Nanoplasmid DNA helps researchers advance scalable gene editing workflows.
Reported by Joshua Diesselhorst